Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 2
2005 1
2006 2
2007 3
2008 2
2010 1
2011 2
2012 1
2013 3
2014 1
2015 1
2016 1
2018 1
2020 5
2021 3
2022 5
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
A therapeutic strategy to target distinct sources of IgE and durably reverse allergy.
Limnander A, Kaur N, Asrat S, Tasker C, Boyapati A, Ben LH, Janczy J, Pedraza P, Abreu P, Chen WC, Godin S, Daniel BJ, Chin H, DeVeaux M, Rodriguez Lorenc K, Sirulnik A, Harari O, Stahl N, Sleeman MA, Murphy AJ, Yancopoulos GD, Orengo JM. Limnander A, et al. Among authors: boyapati a. Sci Transl Med. 2023 Dec 13;15(726):eadf9561. doi: 10.1126/scitranslmed.adf9561. Epub 2023 Dec 13. Sci Transl Med. 2023. PMID: 38091405
Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M, Forleo-Neto E, Pignolo RJ, Keen R, Orcel P, Funck-Brentano T, Roux C, Kolta S, Madeo A, Bubbear JS, Tabarkiewicz J, Szczepanek M, Bachiller-Corral J, Cheung AM, Dahir KM, Botman E, Raijmakers PG, Al Mukaddam M, Tile L, Portal-Celhay C, Sarkar N, Hou P, Musser BJ, Boyapati A, Mohammadi K, Mellis SJ, Rankin AJ, Economides AN, Trotter DG, Herman GA, O'Meara SJ, DelGizzi R, Weinreich DM, Yancopoulos GD, Eekhoff EMW, Kaplan FS. Di Rocco M, et al. Among authors: boyapati a. Nat Med. 2023 Oct;29(10):2615-2624. doi: 10.1038/s41591-023-02561-8. Epub 2023 Sep 28. Nat Med. 2023. PMID: 37770652 Free PMC article. Clinical Trial.
The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.
McAleavy M, Zhang Q, Ehmann PJ, Xu J, Wipperman MF, Ajithdoss D, Pan L, Wakai M, Simonson R, Gadi A, Oyejide A, Hamon SC, Boyapati A, Morton LG, Shavlakadze T, Kyratsous CA, Glass DJ. McAleavy M, et al. Among authors: boyapati a. Mol Cell Biol. 2022 Jan 20;42(1):e0046721. doi: 10.1128/MCB.00467-21. Epub 2021 Nov 1. Mol Cell Biol. 2022. PMID: 34723652 Free PMC article. Clinical Trial.
SERPINB13 is a novel RUNX1 target gene.
Boyapati A, Ren B, Zhang DE. Boyapati A, et al. Biochem Biophys Res Commun. 2011 Jul 22;411(1):115-20. doi: 10.1016/j.bbrc.2011.06.107. Epub 2011 Jun 23. Biochem Biophys Res Commun. 2011. PMID: 21723253 Free PMC article.
Association of complement pathways with COVID-19 severity and outcomes.
Devalaraja-Narashimha K, Ehmann PJ, Huang C, Ruan Q, Wipperman MF, Kaplan T, Liu C, Afolayan S, Glass DJ, Mellis S, Yancopoulos GD, Hamilton JD, MacDonnell S, Hamon SC, Boyapati A, Morton L. Devalaraja-Narashimha K, et al. Among authors: boyapati a. Microbes Infect. 2023 May;25(4):105081. doi: 10.1016/j.micinf.2022.105081. Epub 2022 Dec 7. Microbes Infect. 2023. PMID: 36494054 Free PMC article. Clinical Trial.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
Bumma N, Richter J, Jagannath S, Lee HC, Hoffman JE, Suvannasankha A, Zonder JA, Shah MR, Lentzsch S, Baz R, Maly JJ, Namburi S, Pianko MJ, Ye JC, Wu KL, Silbermann R, Min CK, Vekemans MC, Munder M, Byun JM, Martínez-Lopez J, Cassady K, DeVeaux M, Chokshi D, Boyapati A, Hazra A, Yancopoulos GD, Sirulnik LA, Rodriguez Lorenc K, Kroog GS, Houvras Y, Dhodapkar MV. Bumma N, et al. Among authors: boyapati a. J Clin Oncol. 2024 Jun 16:JCO2401008. doi: 10.1200/JCO.24.01008. Online ahead of print. J Clin Oncol. 2024. PMID: 38879802
35 results